NSCLC

FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer

Leave a Comment
FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer

The FDA has granted an orphan drug designation to rucosopasem manganese (GC4711) for the treatment of patients with pancreatic cancer, according to an announcement from Galera Therapeutics.1 Rucosopasem is a next-generation selective dismutase mimetic being evaluated to improve the activity of stereotactic body radiation therapy (SBRT) in patients with pancreatic cancer and lung cancer. The … [Read more…]

Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC

Leave a Comment
Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC

The combination of osimertinib (Tagrisso) and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to the final analysis of the primary end point of the phase 3 FLAURA2 … [Read more…]